Cargando…
Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis
OBJECTIVES: Skin fibrosis mediated by activated dermal fibroblasts is a hallmark of systemic sclerosis (SSc), especially in the subset of patients with diffuse disease. Transforming growth factor-beta (TGFβ) and interleukin-6 (IL-6) are key candidate mediators in SSc. Our aim was to elucidate the sp...
Autores principales: | Denton, Christopher P, Ong, Voon H, Xu, Shiwen, Chen-Harris, Haiyin, Modrusan, Zora, Lafyatis, Robert, Khanna, Dinesh, Jahreis, Angelika, Siegel, Jeffrey, Sornasse, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104680/ https://www.ncbi.nlm.nih.gov/pubmed/29853453 http://dx.doi.org/10.1136/annrheumdis-2018-213031 |
Ejemplares similares
-
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
por: Khanna, Dinesh, et al.
Publicado: (2018) -
Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014) -
Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis
por: Gao, Xia, et al.
Publicado: (2020) -
Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk
por: Moreno-Moral, Aida, et al.
Publicado: (2018) -
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)